What is Pacific Biosciences of California's D&A?

Pacific Biosciences of California (PACB) reported D&A of $1.54M in Q4 2023.

How has Pacific Biosciences of California's D&A changed year-over-year?

Pacific Biosciences of California's D&A increased by 122.2% year-over-year, from -$6.94M to $1.54M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Pacific Biosciences of California PACB D&A

Discontinued — last reported Q4 '23

D&A at other companies

PDF SolutionsPDFS

$1.06M+54.6%

CohuCOHU

$7.3M-25.9%

CareDxCDNA

$3.9M+8.3%

Charles River LaboratoriesCRL

$67.15M-44.2%

RevvityRVTY

——

Segments

By segment

See full

Reportable Segment$833K-99.8%

Other financials

Income statement

See full

Revenue$37.2M+0.1%

Gross profit$12.8M+1,037%

Operating income-$8.4M+98.1%

Net income-$8.3M+98.1%

EPS (diluted)-$0.03+97.9%

Balance sheet

See full

Cash & equivalents$57.9M-4.7%

Total debt$59.3M+12.1%

Total equity$2.4M-97.4%

Total assets$782.4M-9.1%

Cash flow

See full

Operating cash flow-$44.7M-1.4%

CapEx$3.0M+119%

Free cash flow-$47.7M-5.0%

Valuation

See full

Market cap$496.96M+30.4%

Enterprise value$498.38M+33.5%

P/S3.1×+0.6×

Profitability

See full

Gross margin37.5%+21.3pp

Operating margin-83.3%-38.2pp

Net margin-80.3%-36.1pp

FCF margin-72.6%-20.0pp

Returns & leverage

See full

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Pacific Biosciences of California’s 10-K, filed February 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacific Biosciences of California's D&A?: Pacific Biosciences of California (PACB) reported D&A of $1.54M in Q4 2023.
How has Pacific Biosciences of California's D&A changed year-over-year?: Pacific Biosciences of California's D&A increased by 122.2% year-over-year, from -$6.94M to $1.54M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.